Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Genomic Predictors for Radiation Sensitivity and Toxicity in Breast Cancer—from Promise to Reality

Genomic Predictors for Radiation Sensitivity and Toxicity in Breast Cancer—from Promise to Reality Purpose of ReviewPrecision medicine and personalized treatment recommendations have become standard for systemic therapy decision-making in women with breast cancer. Until recently, however, such opportunities have been lacking for radiation related treatment decisions.Recent FindingsRecent studies have explored the utility of using genomic signatures developed to make systemic therapy recommendations (e.g. Oncotype DX®, ProSigna®, IHC4-C) to guide recommendations for radiation as well. Emerging data suggests that these signatures, while prognostic, may not identify radiation benefit. Radiation-specific signatures are currently under clinical development and may soon be ready for clinical implementation. These classifiers may better be able to determine radiation benefit and detect cancers with intrinsic radiation resistance.SummaryWe are beginning to realize the promise of precision medicine for radiation treatment decisions in women with breast cancer. Previously developed genomic signatures are currently being tested for radiation-related questions, and radiation-specific signatures and radiation toxicity biomarkers are moving into clinical implementation. These advances make clear that genomic classifiers show more than mere promise and will soon allow for personalized radiation recommendations. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Current Breast Cancer Reports Springer Journals

Genomic Predictors for Radiation Sensitivity and Toxicity in Breast Cancer—from Promise to Reality

Loading next page...
 
/lp/springer-journals/genomic-predictors-for-radiation-sensitivity-and-toxicity-in-breast-a0OXuFWFzD
Publisher
Springer Journals
Copyright
Copyright © Springer Science+Business Media, LLC, part of Springer Nature 2020
ISSN
1943-4588
eISSN
1943-4596
DOI
10.1007/s12609-020-00382-z
Publisher site
See Article on Publisher Site

Abstract

Purpose of ReviewPrecision medicine and personalized treatment recommendations have become standard for systemic therapy decision-making in women with breast cancer. Until recently, however, such opportunities have been lacking for radiation related treatment decisions.Recent FindingsRecent studies have explored the utility of using genomic signatures developed to make systemic therapy recommendations (e.g. Oncotype DX®, ProSigna®, IHC4-C) to guide recommendations for radiation as well. Emerging data suggests that these signatures, while prognostic, may not identify radiation benefit. Radiation-specific signatures are currently under clinical development and may soon be ready for clinical implementation. These classifiers may better be able to determine radiation benefit and detect cancers with intrinsic radiation resistance.SummaryWe are beginning to realize the promise of precision medicine for radiation treatment decisions in women with breast cancer. Previously developed genomic signatures are currently being tested for radiation-related questions, and radiation-specific signatures and radiation toxicity biomarkers are moving into clinical implementation. These advances make clear that genomic classifiers show more than mere promise and will soon allow for personalized radiation recommendations.

Journal

Current Breast Cancer ReportsSpringer Journals

Published: Oct 4, 2020

There are no references for this article.